Research ArticleArticle
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis
Attila Feher, Nabil E. Boutagy, Evangelos K. Oikonomou, Stephanie Thorn, Yi-Hwa Liu, Edward J. Miller, Albert J. Sinusas and Monique Hinchcliff
The Journal of Rheumatology July 2021, jrheum.210040; DOI: https://doi.org/10.3899/jrheum.210040
Attila Feher
This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers R01 AR073270 (MH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. A. Feher, MD, PhD, E.K. Oikonomou, MD, PhD, S. Thorn, PhD, Y.H. Liu, PhD, E.J. Miller, MD, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; N.E. Boutagy, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, and Vascular Biology and Therapeutics Program, and Department of Pharmacology, Yale School of Medicine; A.J. Sinusas, MD, BSc, Section of Cardiovascular Medicine, Department of Internal Medicine, and Department of Radiology and Biomedical Imaging, Yale School of Medicine, and Department of Biomedical Engineering, Yale University; M. Hinchcliff, MD, Section of Rheumatology, Department of Internal Medicine, and Department of Internal Medicine, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Hinchcliff, Director, Yale Scleroderma Program, Yale School of Medicine, Section of Allergy, Rheumatology, and Immunology, The Anlyan Center, 300 Cedar Street, PO BOX 208031, New Haven, CT 06520, USA. Email: monique.hinchcliff@yale.edu. Accepted for publication July 5, 2021.
Nabil E. Boutagy
This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers R01 AR073270 (MH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. A. Feher, MD, PhD, E.K. Oikonomou, MD, PhD, S. Thorn, PhD, Y.H. Liu, PhD, E.J. Miller, MD, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; N.E. Boutagy, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, and Vascular Biology and Therapeutics Program, and Department of Pharmacology, Yale School of Medicine; A.J. Sinusas, MD, BSc, Section of Cardiovascular Medicine, Department of Internal Medicine, and Department of Radiology and Biomedical Imaging, Yale School of Medicine, and Department of Biomedical Engineering, Yale University; M. Hinchcliff, MD, Section of Rheumatology, Department of Internal Medicine, and Department of Internal Medicine, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Hinchcliff, Director, Yale Scleroderma Program, Yale School of Medicine, Section of Allergy, Rheumatology, and Immunology, The Anlyan Center, 300 Cedar Street, PO BOX 208031, New Haven, CT 06520, USA. Email: monique.hinchcliff@yale.edu. Accepted for publication July 5, 2021.
Evangelos K. Oikonomou
This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers R01 AR073270 (MH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. A. Feher, MD, PhD, E.K. Oikonomou, MD, PhD, S. Thorn, PhD, Y.H. Liu, PhD, E.J. Miller, MD, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; N.E. Boutagy, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, and Vascular Biology and Therapeutics Program, and Department of Pharmacology, Yale School of Medicine; A.J. Sinusas, MD, BSc, Section of Cardiovascular Medicine, Department of Internal Medicine, and Department of Radiology and Biomedical Imaging, Yale School of Medicine, and Department of Biomedical Engineering, Yale University; M. Hinchcliff, MD, Section of Rheumatology, Department of Internal Medicine, and Department of Internal Medicine, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Hinchcliff, Director, Yale Scleroderma Program, Yale School of Medicine, Section of Allergy, Rheumatology, and Immunology, The Anlyan Center, 300 Cedar Street, PO BOX 208031, New Haven, CT 06520, USA. Email: monique.hinchcliff@yale.edu. Accepted for publication July 5, 2021.
Stephanie Thorn
This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers R01 AR073270 (MH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. A. Feher, MD, PhD, E.K. Oikonomou, MD, PhD, S. Thorn, PhD, Y.H. Liu, PhD, E.J. Miller, MD, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; N.E. Boutagy, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, and Vascular Biology and Therapeutics Program, and Department of Pharmacology, Yale School of Medicine; A.J. Sinusas, MD, BSc, Section of Cardiovascular Medicine, Department of Internal Medicine, and Department of Radiology and Biomedical Imaging, Yale School of Medicine, and Department of Biomedical Engineering, Yale University; M. Hinchcliff, MD, Section of Rheumatology, Department of Internal Medicine, and Department of Internal Medicine, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Hinchcliff, Director, Yale Scleroderma Program, Yale School of Medicine, Section of Allergy, Rheumatology, and Immunology, The Anlyan Center, 300 Cedar Street, PO BOX 208031, New Haven, CT 06520, USA. Email: monique.hinchcliff@yale.edu. Accepted for publication July 5, 2021.
Yi-Hwa Liu
This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers R01 AR073270 (MH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. A. Feher, MD, PhD, E.K. Oikonomou, MD, PhD, S. Thorn, PhD, Y.H. Liu, PhD, E.J. Miller, MD, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; N.E. Boutagy, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, and Vascular Biology and Therapeutics Program, and Department of Pharmacology, Yale School of Medicine; A.J. Sinusas, MD, BSc, Section of Cardiovascular Medicine, Department of Internal Medicine, and Department of Radiology and Biomedical Imaging, Yale School of Medicine, and Department of Biomedical Engineering, Yale University; M. Hinchcliff, MD, Section of Rheumatology, Department of Internal Medicine, and Department of Internal Medicine, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Hinchcliff, Director, Yale Scleroderma Program, Yale School of Medicine, Section of Allergy, Rheumatology, and Immunology, The Anlyan Center, 300 Cedar Street, PO BOX 208031, New Haven, CT 06520, USA. Email: monique.hinchcliff@yale.edu. Accepted for publication July 5, 2021.
Edward J. Miller
This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers R01 AR073270 (MH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. A. Feher, MD, PhD, E.K. Oikonomou, MD, PhD, S. Thorn, PhD, Y.H. Liu, PhD, E.J. Miller, MD, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; N.E. Boutagy, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, and Vascular Biology and Therapeutics Program, and Department of Pharmacology, Yale School of Medicine; A.J. Sinusas, MD, BSc, Section of Cardiovascular Medicine, Department of Internal Medicine, and Department of Radiology and Biomedical Imaging, Yale School of Medicine, and Department of Biomedical Engineering, Yale University; M. Hinchcliff, MD, Section of Rheumatology, Department of Internal Medicine, and Department of Internal Medicine, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Hinchcliff, Director, Yale Scleroderma Program, Yale School of Medicine, Section of Allergy, Rheumatology, and Immunology, The Anlyan Center, 300 Cedar Street, PO BOX 208031, New Haven, CT 06520, USA. Email: monique.hinchcliff@yale.edu. Accepted for publication July 5, 2021.
Albert J. Sinusas
This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers R01 AR073270 (MH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. A. Feher, MD, PhD, E.K. Oikonomou, MD, PhD, S. Thorn, PhD, Y.H. Liu, PhD, E.J. Miller, MD, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; N.E. Boutagy, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, and Vascular Biology and Therapeutics Program, and Department of Pharmacology, Yale School of Medicine; A.J. Sinusas, MD, BSc, Section of Cardiovascular Medicine, Department of Internal Medicine, and Department of Radiology and Biomedical Imaging, Yale School of Medicine, and Department of Biomedical Engineering, Yale University; M. Hinchcliff, MD, Section of Rheumatology, Department of Internal Medicine, and Department of Internal Medicine, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Hinchcliff, Director, Yale Scleroderma Program, Yale School of Medicine, Section of Allergy, Rheumatology, and Immunology, The Anlyan Center, 300 Cedar Street, PO BOX 208031, New Haven, CT 06520, USA. Email: monique.hinchcliff@yale.edu. Accepted for publication July 5, 2021.
Monique Hinchcliff
This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) under Award Numbers R01 AR073270 (MH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. A. Feher, MD, PhD, E.K. Oikonomou, MD, PhD, S. Thorn, PhD, Y.H. Liu, PhD, E.J. Miller, MD, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; N.E. Boutagy, PhD, Section of Cardiovascular Medicine, Department of Internal Medicine, and Vascular Biology and Therapeutics Program, and Department of Pharmacology, Yale School of Medicine; A.J. Sinusas, MD, BSc, Section of Cardiovascular Medicine, Department of Internal Medicine, and Department of Radiology and Biomedical Imaging, Yale School of Medicine, and Department of Biomedical Engineering, Yale University; M. Hinchcliff, MD, Section of Rheumatology, Department of Internal Medicine, and Department of Internal Medicine, Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut, USA. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Hinchcliff, Director, Yale Scleroderma Program, Yale School of Medicine, Section of Allergy, Rheumatology, and Immunology, The Anlyan Center, 300 Cedar Street, PO BOX 208031, New Haven, CT 06520, USA. Email: monique.hinchcliff@yale.edu. Accepted for publication July 5, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis
Attila Feher, Nabil E. Boutagy, Evangelos K. Oikonomou, Stephanie Thorn, Yi-Hwa Liu, Edward J. Miller, Albert J. Sinusas, Monique Hinchcliff
The Journal of Rheumatology Jul 2021, jrheum.210040; DOI: 10.3899/jrheum.210040
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis
Attila Feher, Nabil E. Boutagy, Evangelos K. Oikonomou, Stephanie Thorn, Yi-Hwa Liu, Edward J. Miller, Albert J. Sinusas, Monique Hinchcliff
The Journal of Rheumatology Jul 2021, jrheum.210040; DOI: 10.3899/jrheum.210040